(Q37984206)

English

Aldosterone blockade and the mineralocorticoid receptor in the management of chronic kidney disease: current concepts and emerging treatment paradigms

scientific article published on 15 February 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Aldosterone blockade and the mineralocorticoid receptor in the management of chronic kidney disease: current concepts and emerging treatment paradigms (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

chronic renal insufficiency

1 reference

based on heuristic

inferred from title

author name string

Linda Shavit

1

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Meyer D Lifschitz

2

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Murray Epstein

3

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

language of work or name

0 references

publication date

15 February 2012

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Kidney International

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

81

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

955-968

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

https://scigraph.springernature.com/pub.10.1038/ki.2011.505

0 references

Minireview: Aldosterone and mineralocorticoid receptors: past, present, and future

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.505

7 January 2021

based on heuristic

inferred from DOI database lookup

Aldosterone and mineralocorticoid receptors in the cardiovascular system

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.505

7 January 2021

based on heuristic

inferred from DOI database lookup

Aldosterone blockade: an emerging strategy for abrogating progressive renal disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.505

7 January 2021

based on heuristic

inferred from DOI database lookup

Role of the renin-angiotensin-aldosterone system in vascular remodeling and inflammation: a clinical review

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.505

7 January 2021

based on heuristic

inferred from DOI database lookup

Aldosterone and the vasculature: mechanisms mediating resistant hypertension

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.505

7 January 2021

based on heuristic

inferred from DOI database lookup

Aldosterone antagonism in chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.505

7 January 2021

based on heuristic

inferred from DOI database lookup

Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.505

7 January 2021

based on heuristic

inferred from DOI database lookup

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.505

7 January 2021

based on heuristic

inferred from DOI database lookup

Current guidelines for using angiotensin-converting enzyme inhibitors and angiotensin II-receptor antagonists in chronic kidney disease: is the evidence base relevant to older adults?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.505

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical practice. Stage IV chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.505

7 January 2021

based on heuristic

inferred from DOI database lookup

Hyperkalemia as a constraint to therapy with combination Renin-Angiotensin system blockade: the elephant in the room

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.505

7 January 2021

based on heuristic

inferred from DOI database lookup

Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.505

7 January 2021

based on heuristic

inferred from DOI database lookup

Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.505

7 January 2021

based on heuristic

inferred from DOI database lookup

Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Preventi

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.505

7 January 2021

based on heuristic

inferred from DOI database lookup

Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.505

7 January 2021

based on heuristic

inferred from DOI database lookup

Kidney disease and cardiovascular risk

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.505

7 January 2021

based on heuristic

inferred from DOI database lookup

Mineralocorticoid receptors and cardiovascular damage: it's not just aldosterone

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.505

7 January 2021

based on heuristic

inferred from DOI database lookup

Reconsidering the roles of the mineralocorticoid receptor

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.505

7 January 2021

based on heuristic

inferred from DOI database lookup

Aldosterone-induced activation of signaling pathways requires activity of angiotensin type 1a receptors

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.505

7 January 2021

based on heuristic

inferred from DOI database lookup

Aldosterone-induced organ damage: plasma aldosterone level and inappropriate salt status

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.505

7 January 2021

based on heuristic

inferred from DOI database lookup

Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.505

7 January 2021

based on heuristic

inferred from DOI database lookup

The role of aldosterone in the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.505

7 January 2021

based on heuristic

inferred from DOI database lookup

Mineralocorticoid receptor antagonists and the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.505

7 January 2021

based on heuristic

inferred from DOI database lookup

Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.505

7 January 2021

based on heuristic

inferred from DOI database lookup

Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.505

7 January 2021

based on heuristic

inferred from DOI database lookup

Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.505

7 January 2021

based on heuristic

inferred from DOI database lookup

Proteinuria: an enzymatic disease of the podocyte?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.505

7 January 2021

based on heuristic

inferred from DOI database lookup

Renal damage in primary aldosteronism: results of the PAPY Study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.505

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term renal outcomes in patients with primary aldosteronism

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.505

7 January 2021

based on heuristic

inferred from DOI database lookup

Local renal aldosterone system and its regulation by salt, diabetes, and angiotensin II type 1 receptor

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.505

7 January 2021

based on heuristic

inferred from DOI database lookup

Chronic kidney disease in the United States: a public policy imperative.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.505

7 January 2021

based on heuristic

inferred from DOI database lookup

Chronic kidney disease as a global public health problem: approaches and initiatives - a position statement from Kidney Disease Improving Global Outcomes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.505

7 January 2021

based on heuristic

inferred from DOI database lookup

Early recognition and prevention of chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.505

7 January 2021

based on heuristic

inferred from DOI database lookup

Prevalence of chronic kidney disease in the United States

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.505

7 January 2021

based on heuristic

inferred from DOI database lookup

Renin inhibition: what are the therapeutic opportunities?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.505

7 January 2021

based on heuristic

inferred from DOI database lookup

Aliskiren combined with losartan in type 2 diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.505

7 January 2021

based on heuristic

inferred from DOI database lookup

Chronic kidney disease and mortality risk: a systematic review

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.505

7 January 2021

based on heuristic

inferred from DOI database lookup

The number, quality, and coverage of randomized controlled trials in nephrology.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.505

7 January 2021

based on heuristic

inferred from DOI database lookup

Role of remission clinics in the longitudinal treatment of CKD.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.505

7 January 2021

based on heuristic

inferred from DOI database lookup

Cardiovascular risk and management in chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.505

7 January 2021

based on heuristic

inferred from DOI database lookup

Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.505

7 January 2021

based on heuristic

inferred from DOI database lookup

Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.505

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.505

7 January 2021

based on heuristic

inferred from DOI database lookup

Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotens

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.505

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor bl

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.505

7 January 2021

based on heuristic

inferred from DOI database lookup

Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.505

7 January 2021

based on heuristic

inferred from DOI database lookup

Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.505

7 January 2021

based on heuristic

inferred from DOI database lookup

Beneficial impact of spironolactone in diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.505

7 January 2021

based on heuristic

inferred from DOI database lookup

Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.505

7 January 2021

based on heuristic

inferred from DOI database lookup

Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.505

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.505

7 January 2021

based on heuristic

inferred from DOI database lookup

Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.505

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.505

7 January 2021

based on heuristic

inferred from DOI database lookup

Eplerenone in patients with systolic heart failure and mild symptoms

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.505

7 January 2021

based on heuristic

inferred from DOI database lookup

The role of aldosterone in potassium tolerance: studies in anephric humans

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.505

7 January 2021

based on heuristic

inferred from DOI database lookup

Renin-angiotensin system blockade and the risk of hyperkalemia in chronic hemodialysis patients.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.505

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety of low-dose spironolactone administration in chronic haemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.505

7 January 2021

based on heuristic

inferred from DOI database lookup

Is spironolactone safe for dialysis patients?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.505

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of spironolactone on K(+) homeostasis and ENaC expression in lymphocytes from chronic hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.505

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term low-dose spironolactone therapy is safe in oligoanuric hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.505

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized, double-blind, placebo-controlled trial of spironolactone on carotid intima-media thickness in nondiabetic hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.505

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.505

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of eplerenone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric chronic hemodialysis patients - a pilot study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.505

7 January 2021

based on heuristic

inferred from DOI database lookup

Plasma sodium stiffens vascular endothelium and reduces nitric oxide release.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.505

7 January 2021

based on heuristic

inferred from DOI database lookup

Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.505

7 January 2021

based on heuristic

inferred from DOI database lookup

Impaired endothelium-dependent flow-mediated vasodilation in hypertensive subjects with hyperaldosteronism

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.505

7 January 2021

based on heuristic

inferred from DOI database lookup

Aldactone therapy in a peritoneal dialysis patient with decreased left ventricular function

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.505

7 January 2021

based on heuristic

inferred from DOI database lookup

Aldactone therapy in a peritoneal dialysis patient.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.505

7 January 2021

based on heuristic

inferred from DOI database lookup

Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.505

7 January 2021

based on heuristic

inferred from DOI database lookup

Adoption of spironolactone therapy for older patients with heart failure and left ventricular systolic dysfunction in the United States, 1998-2001.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.505

7 January 2021

based on heuristic

inferred from DOI database lookup

Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.505

7 January 2021

based on heuristic

inferred from DOI database lookup

Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS).

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.505

7 January 2021

based on heuristic

inferred from DOI database lookup

Predictors of hyperkalemia risk following hypertension control with aldosterone blockade

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.505

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.505

7 January 2021

based on heuristic

inferred from DOI database lookup

Mineralocorticoid receptor antagonists: The evolution of utility and pharmacology

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.505

7 January 2021

based on heuristic

inferred from DOI database lookup

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.505

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/KI.2011.505

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37984206&oldid=1736317688"